JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

2014/09/06 by Sandrine Degryse, Charles E. de Bock, Luk Cox +13 · 26 citations
Medicine · #Acute Lymphoblastic Leukemia research #Chronic Myeloid Leukemia Treatments #Myeloproliferative Neoplasms: Diagnosis and Treatment

paper · pdf · doi:10.1182/blood-2014-04-566687

Abstract

JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vitro and in vivo assays. Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOHITO cell lines to cytokine-independent proliferation. JAK3 pseudokinase mutants were dependent on Jak1 kinase activity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak1 kinase-independent manner. Reconstitution of the IL7 receptor signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downstream STAT5 phosphorylation. Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-ALL-like disease, characterized by an accumulation of immature CD8(+) T cells. In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis. Our data show that JAK3 mutations are drivers of T-ALL and require the cytokine receptor complex for transformation. These results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

Cited by

• Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
• In-situ tumor vaccination: Bringing the fight to the tumor. [europepmc]
• Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma. [europepmc]
• Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. [europepmc]
• IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. [europepmc]
• The genetics and molecular biology of T-ALL. [europepmc]
• The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. [europepmc]
• Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. [europepmc]
• Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. [europepmc]
• IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update. [europepmc]
• A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. [europepmc]
• Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. [europepmc]
• Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. [europepmc]
• Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. [europepmc]
• The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. [europepmc]
• JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. [europepmc]
• Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. [europepmc]
• Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. [europepmc]
• JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). [europepmc]
• Janus Kinases in Leukemia. [europepmc]
• Deregulation of JAK2 signaling underlies primary cutaneous CD8 + aggressive epidermotropic cytotoxic T-cell lymphoma. [europepmc]
• Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. [europepmc]
• Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies? [europepmc]
• Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. [europepmc]
• PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. [europepmc]
• Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. [europepmc]

Related

• Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
• JAK mutations in high-risk childhood acute lymphoblastic leukemia
• The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
• The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
• Germline Gain-of-Function <i>JAK3</i> Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells